The global Antibiotic Resistance Market size is estimated to
reach USD 12.07 billion by 2025. According to a new report by Grand View
Research, Inc., it is anticipated to post a CAGR of 5.6% during the forecast
period. Rising burden of antibiotic-resistant infections and emergence of
multi-drug resistant pathogens has been driving the market.
Biotech companies that are developing therapies for
antibiotic-resistant infections include Melinta Therapeutics, Achaogen, and
Nabriva Therapeutics. On the other hand, majority of large pharmaceutical
companies don’t find this market lucrative enough due to slower growth in
revenues for marketed drugs and lower return on investments. For instance,
Novartis recently discontinued development of its antibacterial drugs for
antibiotic resistance.
Manufacturers can obtain the Qualified Infectious
Disease Product (QIDP) designation, which escalates the clinical review process
for antibacterial therapies targeting high priority pathogens. The QIDP
designation enables faster access to targeted agents and was introduced under
the GAIN (Generating Antibiotic Incentives Now) Act, passed in 2012 as an
extension to the U.S. FDA Safety and Innovation Act. The legislation aims to
encourage the development of novel therapies for growing burden and severity of
infections with antibiotic resistance.
Browse Details of Report @
Further key findings from
the report suggest:
- In
2017, the market by cUTI disease registered significant sales due to
elevated rate of resistance in extended-spectrum beta-lactamase
(ESBL)-producing and carbapenem-resistant Enterobacteriaceae and P.
aeruginosa strains
- The
combination therapies segment, which includes fixed-dose combinations of
beta lactams and beta lactamase inhibitors, is projected to witness the
fastest growth rate over the forecast period
- Infections
due to E. coli pathogens that are ESBL-producing and carbapenem-resistant
led in terms of sales revenue in 2017 due to high treatment cost
- On
the geographical front, North America was the dominant revenue contributor
in the market in 2017. Improving reimbursement scenario with new
technology add-on payment provision is promoting the use of novel products
in this region
- Among
pharmaceutical companies, Merck, Allergan, and Pfizer were the key players
with top-selling drugs in the antibiotic resistance market in 2017.
About Us:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
Blog: https://healthcareforecastreport.blogspot.com/
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
Blog: https://healthcareforecastreport.blogspot.com/
No comments:
Post a Comment